Dr. Bekaii-Saab delved into the latest advancements in the treatment of metastatic pancreatic cancer, including the recent approval of Nalirifox in the United States and how it compares to the traditional standard of care, Folfirinox. Dr. Bekaii-Saab shared insights on the selection of treatment regimens, the importance of managing toxicities, and the role of next-generation sequencing (NGS) in identifying potential targets for therapy.